Publications by authors named "Xiao-Ran Gu"
Adverse events of atrial fibrillation (AF) have been commonly reported in lymphoma patients in treating Bruton's tyrosine kinase inhibitors (BTKi). The incidence rate of AF can vary depending on the specific types of BTKi and the patient population. Totally 45 published studies have revealed that the overall incidence rate of AF is 5% (95% CI 4%-7%).
View Article and Find Full Text PDFArticle Synopsis
- The incidence of multiple myeloma (MM) is increasing, and while new treatments have improved outcomes, the disease remains incurable; understanding the chemokine network's role in MM could lead to better biomarkers and therapies.
- This research reviews the complex roles of various chemokines in MM, identifying which can be used as biomarkers and exploring potential treatments that target these chemokines.
- Findings suggest that some chemokines help cancer cells evade treatment while others can enhance immune responses; new therapeutic strategies, including anti-tumor chemokines and combinations with CAR-T therapy, show promise for future clinical use.
Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system. Although treatment methods for MM have been continuously improved and the survival of patients has been dramatically prolonged, MM remains an incurable disease with a high probability of recurrence.
View Article and Find Full Text PDF